COMPARE · Data as of August 24, 2026
GRFS vs VTRS
Verdict: Side-by-side breakdown using the Bull Rankings model. GRFS scored 70.9, VTRS scored 50.1 — GRFS leads.
Compare another set
GRFS
Grifols, S.A.
70.9
$7.99 · $5.4B
Score gap
20.8
GRFS leads
VTRS
Viatris Inc.
50.1
$16.54 · $19.0B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Fastest growthGRFS+9.4%
- Strongest balance sheetVTRS0.96
- Highest qualityGRFS56 / 100
- Largest discount to fair valueGRFS-49%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
GRFS
stronger →← stronger
VTRS
56
Qualityreturns · margins · balance sheet
38
77
Growthrevenue & earnings expansion
42
96
Valuevaluation vs sector peers
77
GRFS is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
GRFS
VTRS
$569mC+
FCF
$2.0bC+
+9.4%B
Rev
+4.5%C+
1.17C
D/E
0.96C
10.4xA
P/E
—
0.19A
PEG
1.05B+
—
P/S
1.3xA-
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
GRFS
VTRS
49% below
Price vs fair valuelower is cheaper
44% below
~-4%/yr
Growth the price implies10-yr FCF · lower = less priced in
~-9%/yr
+57%
1-yr DCF upside
+71%
+97%
5-yr DCF upside
+80%
+171%
10-yr DCF upside
+93%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
GRFS
Why this score
- Raising its dividend
- Foreign reporter (EUR)
VTRS
The companies
GRFSGrifols, S.A.
Why now
Drug Manufacturers - General · market cap $5.4b. Down 22% from 52-week high of $10.23 — deep drawdown territory. PEG 0.19 — paying under fair value for the growth rate.
Moat
FCF converts 108% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Net margin 3.0% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first. ROE 2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
VTRSViatris Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $19.0b. 10% off the 52-week high of $18.39. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $18.50 (implying +12% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -23.9%) — path to GAAP profitability is the core thesis risk. ROE -25% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Patent cliff exposure — a single approved molecule can carry the company; when patent protection expires, generic / biosimilar competition can erase 80% of the revenue in 2-3 years.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where GRFS and VTRS diverge
On the headline score the gap is 20.8 points in favor of GRFS. The widest single difference is Growth, where GRFS leads by 34.7 points.
- GrowthGRFS 77.0 · VTRS 42.3GRFS +34.7
- ValueGRFS 96.3 · VTRS 77.5GRFS +18.8
- QualityGRFS 56.1 · VTRS 38.4GRFS +17.7
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.